Pharmacogenomics: Personalizing palliative pharmacotherapy.

Authors

null

Caleb Scheckel

Mayo Clinic Department of Internal Medicine, Division of Hematology and Medical Oncology, Rochester, MN

Caleb Scheckel, Adrijana Kekic, Mark Edwin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Mental Health and Psychological Well-being,Psychosocial and Spiritual/Cultural Assessment and Management,Models of Care,Patient Reported Outcomes and Patient Experience,Prevention, Assessment, and Management of Disease and Treatment-related Symptoms,Prognostication ,Survivorship and Late Effects of Cancer

Sub Track

Prevention, Assessment, and Management of Disease and Treatment-related Symptoms

Citation

J Clin Oncol 37, 2019 (suppl 31; abstr 126)

DOI

10.1200/JCO.2019.37.31_suppl.126

Abstract #

126

Poster Bd #

E3

Abstract Disclosures

Similar Posters

Poster

2019 Supportive Care in Oncology Symposium

Pharmacogenetic (PGx) guided cancer pain management in an oncology palliative medicine (PM) clinic.

Pharmacogenetic (PGx) guided cancer pain management in an oncology palliative medicine (PM) clinic.

First Author: Jai Narendra Patel

Poster

2020 ASCO Virtual Scientific Program

Improving cancer pain control: Potential impact of <em>CYP2D6</em> pharmacogenomic (PGx) testing in oncology (Onc) patients.

Improving cancer pain control: Potential impact of CYP2D6 pharmacogenomic (PGx) testing in oncology (Onc) patients.

First Author: Natalie Reizine

Poster

2017 ASCO Quality Care Symposium

Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.

Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.

First Author: Dominic Pilon

First Author: Carlos A. Farfán